Identification and Validation of Functional Biomarkers for Keratoconus
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
There is currently no medication for containing KC, nor any adequate biomarkers to predict
the disease. Furthermore, there is considerable confusion in the field regarding the
pathophysiology of the disease and involvement of inflammation. To that end, this study is
designed to address some of these questions by determining the proteomic profiles of KC
patients with different clinical grades. This relatively large cohort study is expected to
yield significant information regarding the molecules that are deregulated during progression
of KC and may provide a framework to assign diagnostic biomarkers and therapeutic
intervention points.